Skip to content
‹ Back to IndustriesSciences

How Basic Chemicals are Being Impacted in the Supply Chain

Key Points: Supply Chain Issues are causing disruptions to the chemical industry. Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions. The big players figured out how to deal with disruptions in the supply chain. Commentary: Disruptions in the supply chain are causing problems across every industry. Basic chemicals, such as…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Basic ChemicalsChemical Supply ChainPrice SurgePvc
Share

Key takeaways

01

Key Points: Supply Chain Issues are causing disruptions to the chemical industry.

02

Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions.

03

The big players figured out how to deal with disruptions in the supply chain.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Key Points:

  • Supply Chain Issues are causing disruptions to the chemical industry.
  • Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions.
  • The big players figured out how to deal with disruptions in the supply chain.

Commentary:

Disruptions in the supply chain are causing problems across every industry. Basic chemicals, such as ethylene, PVC, and epoxy resins, are seeing price surges due to these disruptions. We asked Jimmy Jett, CEO of Integrity BioChem, about these demand increases and what sort of role does it play in the overall chemical supply chain issue.

Abridged Thoughts:

Obviously, demand. There is a lot of pent-up demand from the pandemic, as people start to consume more and get back on the roads and travel. You’re seeing a lot of demand. It is unfortunate that demand is spiking, as supply is dwindling. What you’re seeing is that the big players have more sophisticated supply chain systems and have gotten out ahead of it. Some great examples are you’ve seen some of the bigger companies that have even contracted their own fleet to move goods and services around the world. You’re seeing some of the larger players with a really solid plan to mitigate some of the supply chain issues, but the Tier Two and Three companies might not have the cash flow to go out and purchase six months worth of inventory. 

What Can the Pharma Industry Learn from Merck’s New Antiviral?

Will Consumers Be Seeing Higher Prices as the Result of the Tightened Supply Chain?

Video TranscriptExpand ↓

Disruptions in the supply chain are causing problems across every industry. Basic chemicals such as ethylene, PVC and epoxy resins are seeing price surges due to these disruptions. With that in mind, we asked Jimmy, CEO of integrity biochim. About this increases in the man and what sort of role does it play in the overall chemical supply chain issue? You know, obviously demand there's a lot of pent up demand from the pandemic as people start to consume more and get back on the roads and travel. You're seeing a lot of demand, and it's unfortunate that demand is spiking as supply is dwindling. So what you're seeing is the big players that have a more sophisticated supply chain system have gotten out ahead of it. Some great examples or you've seen a lot of the bigger companies that have even contracted their own fleet to move goods and services around the world. And so you're seeing some of the larger players with a really solid plan to mitigate a lot of the supply chain issues. But the tier two and tier three companies that might not have the cash flow to go out and purchase six months worth of inventory are feeling it the most and you're going to see. And then the reality is in the US that tier two and tier three support system in manufacturing than in the chemical space that goods and services, it makes up a massive percentage of the market. So you're going to see a very compressed manufacturing base that are able to get the products. And so with that are going to come a lot of delays. You can just expect, you know, lead times to go from 2 to three weeks to six months and even pushed out further. So it's going to be interesting as the market tries to correct. We already know what these issues are doing to chemicals such as ethylene, PVC and epoxy resins. But what about the sustainable, bio based chemicals? Are they being impacted similarly or in a completely different way? So the sustainable supply chain, you know, the surfactants or the based surfactants and the chemical side have not been impacted. But what you're going to find is that a lot of the technology out there, you obviously don't have the production capacity that is built into their traditional synthetic market. So a lot of the fermentation capacity has come a long way and you're going to see them surge over the next six months because they're going to be able to produce what they can. However, what they can produce is just a fraction of what the industry needs. A lot of the vegetative sources like integrity biochem uses, they're going to be more readily available as well, but they're emerging technologies and they might not have the adoption that traditional synthetics have. So it's going to be interesting to see how quickly you can get these chemistries into the supply chain and through the regulatory side in an expedited way to make an impact. Finding solutions to these supply chain issues is something every industry is trying to figure out when it comes to chemical producers. What strategies should they implement westjet? Should they be investing in New supply chain partnerships, new chemical compounds or new production workflows? And this is what he had to say. I think it's definitely a mix. I mean, you have to be looking at alternative supply partners immediately to secure the pent up demand that is required to run your business. But, you know, in a congruent path, you need to be also looking at New technologies that might supplement or even replace some of these existing technologies. You know, one of the things I love about this industry is that innovation is born in difficult supply markets. When there's challenges out there, a lot of new stuff is developed and a lot of new markets are created. So I'm excited to see what happens. I mean, America is we are excellent at adapting. And so I think we're going to see a lot of neat new technologies emerge and a lot of sustainable products that might have been on the sidelines are going to have a shot to come in and replace some of the sympathetics that you just can't get right now. Chemical energy and its demands is something that needs to be closely evaluated, especially when it's in high demand and a supply chain process is facing as many issues as it is. For more stories of energy and its supply chain effects, be sure to head to Marcus gmail.com as well as subscribe.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz's AAV2 gene therapy for retinitis pigmentosa, through IND-enabling work and a planned Phase 1/2 trial. CLZ002 targets retinal repair, not mutations. Because the disease is linked to more than 90 genes, one manufacturing process could end up serving a broad patient group.

  • 01Retinitis pigmentosa has more than 90 causal genes; CLZ002 aims at a shared retinal repair pathway, so a single AAV2 manufacturing process would serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab hiring budgets for 2027 carry a net outlook of just +2, down from +10, while consumables sit at +30 and raw materials at +31. Labs are paying for supplies and planning capital purchases further ahead. New positions face the toughest scrutiny.

  • 01Labs heading into 2027 expect their reagent budgets to grow and their headcount budgets to stall: consumables carry a net outlook of +30, hiring just +2.
  • 02Lab Manager’s read: if consumables spending stays flat, the lab is probably buying less—because respondents reported rising costs across many supply items, from reagents to shipping.
  • 03Hiring gets treated as a recurring cost, not a one-time purchase; one published example estimates ~$46,000/year for a graduate student and $80,000–$100,000 for a postdoc (with fringe) at one institution. Lab Manager recommends justifying new roles with throughput, turnaround and risk—while separating price from volume in supply-line requests.

Nov 13, 2026

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra BioPharma Solutions opened Building H, a $250 million-plus addition to its Bloomington, Indiana campus, featuring two syringe lines and a vial line with lyophilizers. The CDMO plans to expand from 11 to 18 filling lines by 2027. Extra sites reduce supply risk only when products are qualified at both locations.

  • 01Simtra's network is set to grow from 11 to 18 filling lines across Indiana and Germany by 2027, a published capacity timeline sponsors can plan tech transfers against.
  • 02A second fill site cuts supply risk only after a product has been validated there; for biologics that means process validation, comparability work and regulatory filings first.
  • 03Programs whose real exposure sits in concentrated starting-material supply gain little from added fill-finish redundancy, however well the new lines are built.

Nov 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512